Cadila Healthcare receives FDA OK to market generic Warfarin tablets

By Angela McDaniels

Seattle, June 1 - Cadila Healthcare Ltd. said it has received approval from the Food and Drug Administration to market generic Warfarin anti-coagulant tablets in 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg 6 mg, 7.5 mg and 10 mg strengths. The group plans to launch the product by the end of June.

Sales of Warfarin reached more than $210 million in 2005, according to a company news release.

The Mumbai, India-based pharmaceutical products company said it will likely have a competitive advantage in marketing the tablets as it will use an active pharmaceutical ingredient manufactured at its own FDA-approved manufacturing facility in Dabhasa, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.